FMBA Institute has applied for registration of the drug from covid “Mir-19”
The “Institute of Immunology” of the Federal Medical and Biological Agency has submitted to the Ministry of Health of the Russian Federation documents for registration of the drug for the treatment of coronavirus “Mir-19” (the name stands for small interfering RNA). According to TASS, the application was registered the day before, on October 14.
The drug is intended for the prevention and treatment of covid through inhalation or intranasal administration.
Mir-19 stops the replication of the virus and prevents the most severe forms of the disease, as well as pneumonia.
The drug showed maximum efficiency in the first two to three days after human infection.
The FMBA Institute received a patent for this drug this spring.
